Newrotex is a UK-based biotech firm using silk biomaterials to create medical solutions for the nervous system. A firm eligible for Knowledge-Intensive EIS funding, our first product…
While our inaugural biomedical application is focused on peripheral nerve injuries (PNI), our future verticals include central nervous system (CNS) repair, organoids for testing CNS pharmaceuticals, and drug/growth factor delivery vehicles.
Read Our Solution page for more details on our luminal silk fibres and silk conduits.
The first Newrotex solution is a simple two-component, off-the-shelf product set to disrupt the standard approaches to peripheral nerve injuries. Our patented silk-based nerve conduit is on track for final pre-clinical testing before stepping into first-in-human trials.
Headquartered in the research-rich “Golden Triangle” of UK universities in Oxford, Cambridge, and London. Newrotex maintains deep connections with the academic community, while establishing strong relationships in the area’s innovative commercial sector.
Our offices, laboratory, and clean-room space are located in the Oxford Science Park, a thriving nexus where science, technology, and business converge.
By taking full advantage of our own clean room facilities, we ensure a manufacturing quality that meets or exceeds the criteria required for human testing. This allows us to conduct trials and provide data directly for escalation to humans and regulatory approval.
A trauma and orthopaedic surgeon, Dr Woods has extensive experience in silk technology and medical devices. He holds a D.Phil in Zoology and a Bachelor of Medicine, Bachelor of Surgery from Oxford University.
Dr Plowright has 5 years of experience developing functionalised silks for biomedical applications and extensive experience with the silk conduit IP.
Andrew joined Newrotex as Chief Commercial Officer in Oct 2022. Andrew holds an MBA and is a professionally qualified marketer. He has had extensive international experience in firms ranging in scale from university “start-ups” through to global multinationals. Andrew’s senior leadership experience includes sales management, marketing, purchasing and supply and general management, and he has consulted in the commercialisation of innovative science based products and services. Most recently, Andrew has served as CEO of a successful medical services company.
Jessica joined Newrotex in the summer of 2022 with 5 years proven laboratory experience working to GLP, MHRA and ISO standards. She has experience in biomedical laboratories leading day-to-day operations, developing assays, troubleshooting laboratory processes and implementing internal quality assurance.
Sharon is a qualified AAT bookkeeper and has a professional diploma in Accounting. She has worked with Startup companies in finance since 2016.
Chris Jones has been a Director of Becton Dickinson since 2010, holding a seat on the board’s Executive Committee. He served as the Board Chair at Cello Health until its acquisition in Aug 2020, is a trustee of the Lasker Foundation, and has been on the Health Advisory Board at Johns Hopkins Bloomberg School of Public Health since 1997.
Professor Vollrath leads the Oxford Silk Group at the University of Oxford and has experience as the founder and director of several start-ups, including Oxford Biomaterials and Neurotex. He holds an MSc in Neurobiology and has extensive expertise with silk and silk-based devices.
Lucy Woods is an experienced CEO, having managed businesses with substantial turnaround requirements for the past 16 years. She was named an EY Entrepreneur of the Year in 2020.
James Mallinson has over 25 years of experience as a VC advisor, both at the seed and later stages. He managed the University of Oxford’s technology spinout portfolio for 15 years, eventually as Director of Oxford Spinout Equity Management.